NCCN guidelines highlight ‘complicated’ treatment for pediatric lymphomasJanuary 14, 2020Aggressive LymphomasPediatricsDLBCLLymphoma & Plasma Cell Disorders
9/11 responders show increased risk of leukemia, other cancersJanuary 14, 2020Leukemia, Myelodysplasia, TransplantationAML
Genomic profiling of AML and MDS yields prognostic cluesJanuary 9, 2020AMLLeukemia, Myelodysplasia, Transplantation
CAR T cells produce complete responses in T-cell malignanciesJanuary 7, 2020ALLLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patientsDecember 23, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Survival data reported from largest CAR T trial in B-cell lymphomaDecember 20, 2019Lymphoma & Plasma Cell DisordersDLBCL
Age, sex, and other factors linked to risk of intracranial hemorrhage in ITPDecember 17, 2019Bleeding Disorders
D-RVd for frontline myeloma looks robust in GRIFFIN trial updateDecember 17, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Zanubrutinib achieved high response rate in del(17p) CLL cohortDecember 16, 2019Leukemia, Myelodysplasia, Transplantation
Some MCL patients can safely stop venetoclax-ibrutinib, study suggestsDecember 14, 2019Lymphoma & Plasma Cell Disorders
KTE-X19 produces highest response rate in MCL subgroupDecember 14, 2019Lymphoma & Plasma Cell Disorders
Orelabrutinib could be ‘preferred’ BTK inhibitor for MCLDecember 12, 2019Lymphoma & Plasma Cell Disorders
